Nicardipine HAT Antioxidant Formulation for Pyridine Impurity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
1,4-dihydropyridines (DHPs) are susceptible to oxidative and photolytic degradation, forming less active pyridine analogues, which is exacerbated during commercial production, leading to decreased therapeutic efficacy and increased toxicity, and existing stabilization methods are inadequate.
Innovation Solution
A stabilized pharmaceutical composition of 1,4-dihydropyridines with hydrogen atom transfer (HAT) antioxidants, comprising nicardipine hydrochloride, HAT antioxidants like ascorbic acid, and other excipients, is formulated to maintain stability and reduce pyridine analog impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 1,4-dihydropyridines are used as calcium channel blockers, then therapeutic efficacy is achieved, but oxidative degradation forms inactive pyridine analogues reducing stability
Solution Approach 1:
The patent introduces hydrogen peroxide as an intermediary substance that mediates the oxidation of 1,4-dihydropyridines to pyridine analogues. By identifying hydrogen peroxide as the active oxidizing agent, the formulation can control or prevent its formation to stabilize the DHP compound.
Solution Approach 2:
The patent modifies formulation parameters including pH, temperature, and the presence of metal ions to control the oxidation rate. By adjusting these parameters, the degradation pathway is controlled to maintain therapeutic efficacy while improving stability.
2Productivity
If commercial aseptic manufacturing is used, then production scalability is achieved, but pyridine analog impurity formation increases significantly
Solution Approach 1:
The patent applies preliminary actions during manufacturing by pre-saturating the formulation with inert gases to remove dissolved oxygen, and by pre-adjusting pH and metal ion content before aseptic filling. These preliminary measures prevent impurity formation during commercial production.
Solution Approach 2:
The patent uses an inert atmosphere approach by filling vials with nitrogen or other inert gases to displace oxygen before aseptic filling. This creates an oxygen-free environment that prevents oxidative degradation during commercial manufacturing while maintaining scalability.
3Ease of manufacture
If hydrogen peroxide residues remain from sanitization, then area cleaning is achieved, but oxidation of DHP to pyridine analogues is catalyzed
Solution Approach 1:
The patent converts the harmful effect of hydrogen peroxide residues into a beneficial control mechanism by identifying it as the specific oxidant responsible for degradation. This allows the formulation to target and control hydrogen peroxide levels specifically, transforming the problem into a controllable parameter.
Solution Approach 2:
The patent extracts and removes hydrogen peroxide from the formulation environment by using reducing agents that specifically target and eliminate hydrogen peroxide residues from sanitization areas, preventing its catalytic oxidation effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves enhanced stability, maintaining at least 90% potency for extended periods, reducing pyridine analog impurities to less than 1%, and ensuring therapeutic effectiveness.
Implementation Method 1
The HAT antioxidant donates a hydrogen atom to the DHP compound, forming a stable radical that terminates the degradation chain.
Implementation Method 2
The HAT antioxidant acts as a radical scavenger, intercepting reactive oxygen species before they can attack the DHP compound.
Data Source
AI summary
A stabilized pharmaceutical composition of 1,4-Dihydropyridines (DHP) incorporating hydrogen atom transfer (HAT) antioxidants is disclosed. The composition comprises nicardipine hydrochloride, a pharmaceutically acceptable DHP salt, at concentrations of 0.1 mg/mL to 5 mg/mL. The HAT antioxidants, such as ascorbic acid or Butylated hydroxyanisole (BHA), are added in amounts of 0.001 mg/mL to 25 mg/mL to prevent the sensitization of DHP compounds observed in the commercial production area. Additionally, co-solvents like sorbitol, mannitol or ethanol, ranging from 0.1 to 10 weight percent, enhance solubility. Buffering agents maintain pH between 3 to 5, while tonicity agents adjust osmolarity to 250 mOsm/kg to 350 mOsm/kg. The composition's formulation involves mixing nicardipine hydrochloride with co-solvents, buffering agents, and antioxidants at temperatures of 5° C. to 30° C. Final sterilization is achieved through filtration or terminal moist heat sterilization, ensuring product safety. This pharmaceutical composition offers enhanced stability, solubility, and efficacy, providing a promising treatment option for cardiovascular conditions.